Astrazeneca Plc ADR (NQ: AZN )
67.26 +0.69 (+1.04%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
All News about Astrazeneca Plc ADR
P/E Ratio Insights for AstraZeneca
March 16, 2023
A Look Into AstraZeneca's Debt
March 15, 2023
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
March 15, 2023
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D...
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
March 14, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival...
Exposures Product Safety
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via Talk Markets
Johnson & Johnson: Taking The Bull By The Horns?
February 21, 2023
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Exposures Intellectual Property Legal Regulatory
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following